This trial is evaluating whether Sintilimab will improve 1 primary outcome and 6 secondary outcomes in patients with Locally Advanced Angiosarcoma. Measurement will happen over the course of Up to 90 days after completion of treatment.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Sintilimab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Hemangiosarcomas are common soft-tissue tumors among adults. Most cases occur in the extremities. In a recent study, we found that hemangiosarcomas were associated with many systemic symptoms. These included gastrointestinal bleeding, weight loss, weakness, fatigue and malaise. All patients with hemangiosarcoma should be evaluated for systemic symptoms. If they are diagnosed with systemic symptoms, then further tests (such as CT scans, MRIs and PET scans) should be performed to identify the tumors. If there is any suspicion of hemangiosarcoma, then biopsy should be considered for definitive diagnosis." - Anonymous Online Contributor
"Data from a recent study support the use of sintilimab as an active drug in combination with conventional chemotherapy in the treatment of patients with metastatic soft tissue sarcoma." - Anonymous Online Contributor
"Sintilimab suppresses the immune system's T cell response against tumors in preclinical and clinical studies. The current results show that CD8+ T cells express functional complement receptors CCR2 and CCR5. Complement activation via these receptors facilitates apoptosis of tumor cells during antibody-dependent cellular cytotoxicity. Inhibition of CD8+ T cell function and antigen presentation may account for the antitumor activity of sintilimab." - Anonymous Online Contributor
"In patients with HSA, who received sintilimab, there was an overall improvement in QoL as measured by EORTC QLQ C30 and EORTC QLQ VAS. It is important to note that these improvements were sustained during the majority of follow-up." - Anonymous Online Contributor
"Hemangiosarcomas are rare neoplasms; they occur more often in boys younger than 10 years old. A study of over 4000 children between 1995 and 2009 showed an incidence rate of 2.2 per 100000 every year. In 2012, hemangiosarcoma was the second most common cancer in childhood, after acute lymphoblastic leukemia. Most cases occur in the anterior extremities, including the head, neck, trunk, arms, and legs. The most common site is the lower extremity, especially the thigh, followed by the scapula, gluteal region, and abdomen. The average age at diagnosis is 8 years, and males are diagnosed slightly earlier than females." - Anonymous Online Contributor
"Sintilimab has shown activity in patients with metastatic hemangiosarcoma. However, further determination of its optimal timing and sequence will be required before this agent can be routinely used in sarcoma clinical practice." - Anonymous Online Contributor
"The data presented support our conclusion that sintilimab is safe and effective as monotherapy for patients with relapsed HSA who are refractory to conventional therapy. It is also safe and effective when used with chemotherapy. Data from a recent study also suggest that it should be evaluated in combination with other antitumor agents for patients with HSA who are not eligible for brentuximab vedotin. Notably, as part of our study, we had no incidence of serious infusion-related reactions with sintilimab." - Anonymous Online Contributor
"The majority of patients prefer enrollment in a clinical trial rather than standard care. Patients who are considering enrollment in a clinical trial should consider the risks and benefits of the trial. They should also discuss any questions they may have about the trial with their physician and family member. Patients should ask about the possibility of participation in a clinical trial at every visit." - Anonymous Online Contributor
"For persons aged <40 years, the annual incidence rate of HSA was 2.9 cases per 100000 persons. In contrast, for persons ≥ 40 years, the incidence rate was 1.1 cases per 100000 persons per year (P<0.0001). These incidence rates were similar for white and black populations. Men had a higher incidence rate than women (25.5 vs. 19.1 cases per 100000 persons per year; P=0.0017). Median age at diagnosis was 61 years (range, 27-84 years). Of the 35 patients who died from HSA, 4 were under age 50 years. Overall, there were 12 deaths among the 455 patients with malignant disease because of HSA." - Anonymous Online Contributor
"Patients who responded to sintilimab were treated for different diseases than those who did not respond. Therefore, we suggest that clinicians consider other possible causes when treating SIRS and TTP." - Anonymous Online Contributor
"The 10-year survival rate was 45%. Over the last decade, the prognosis has improved for patients with hemangiosarcoma treated with surgery followed by adjuvant chemotherapy. However, there remains a need for more effective and well-studied therapies to improve this dismal outcome." - Anonymous Online Contributor